---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-095508"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:57:25.992387+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma extends cooperation with Rubric Capital; Justin Roberts to remain on board through 2025 AGM

## Summary
- Extension letter dated April 15, 2024 waives resignation requirement for director Justin Roberts after 2024 AGM.
- Termination date of Cooperation Agreement extended to immediately after the 2025 annual shareholder meeting.
- Cooperation Agreement originally dated October 28, 2022 between Mereo and Rubric Capital Management L.P.

## SEC filing metadata
- accession: 0001193125-24-095508
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/0001193125-24-095508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/d818381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-095508
- JSON: https://secwatch.observer/filing/0001193125-24-095508.json
- Plain text: https://secwatch.observer/filing/0001193125-24-095508.txt

## Key facts
- Material Agreements
  Mereo BioPharma Group plc entered into Extension Letter to Cooperation Agreement with Rubric Capital Management L.P. valued at Extension Letter waiving resignation requirement and extending termination date to after 2025 annual (effective 2024-04-15).
  - Action: entry
  - Counterparty: Rubric Capital Management L.P.
  - Value: Extension Letter waiving resignation requirement and extending termination date to after 2025 annual
  - Effective: 2024-04-15
  source text: On April 15, 2024, Mereo BioPharma Group plc (the “Company”) entered into an extension letter, effective as of April 15, 2024 (the “Extension Letter”) to the cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Company and Rubric Capital Management L.P. (“Rubric Capital”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312524095508/0001193125-24-095508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.